Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT03393273 | Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell…(IFM2016-03) | Phase 2 | withdrawn | Jan 8, 2018 | Assistance Publique - Hôpitaux de Paris | Investigator decision in accordance with the promotor | Investigator |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | Phase 1 / Phase 2 | terminated | Jun 11, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple… | Phase 2 | terminated | Nov 7, 2017 | Yvonne Efebera | Study was discontinued due to FDA recommendations of the potential toxicities of the combination of… | Safety / toxicity |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | Phase 1 / Phase 2 | terminated | Sep 20, 2016 | Mayo Clinic | pursuing IND | Other (stated, no rule matched) |
| NCT01927718 | Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell… | N/A | terminated | Aug 23, 2013 | M.D. Anderson Cancer Center | Poor Response Rate | Other (stated, no rule matched) |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Feb 27, 2019 | National Cancer Institute (NCI) | Per CTEP, Martha Khrum this study is withdrawn. Changing status to update CT.gov | Other (stated, no rule matched) |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in… | Phase 2 | withdrawn | Jul 18, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With… | Phase 2 | terminated | Jun 15, 2009 | Sirtris, a GSK Company | Study terminated.24 subjects enrolled;provided adequate data for decision making. | Enrollment / accrual |
| NCT03168100 | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule… | Phase 2 | withdrawn | May 30, 2017 | University of Arkansas | No study population. No subjects enrolled. | Enrollment / accrual |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | Phase 2 / Phase 3 | terminated | May 23, 2014 | Dr. med. Lars-Olof Muegge | Insufficient recruitment | Enrollment / accrual |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | Phase 2 | terminated | Jul 14, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | MEDI-551 removed from oncology by pharmaceutical company due to change in research target. | Sponsor / business decision |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | Phase 1 / Phase 2 | terminated | Jul 4, 2013 | Adaptimmune | Sponsor Decision | Sponsor / business decision |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple… | Phase 1 / Phase 2 | terminated | Feb 25, 2011 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | Phase 2 | withdrawn | Nov 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or… | Phase 3 | terminated | Nov 11, 2011 | AB Science | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in… | Phase 2 | terminated | Jun 15, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | early stopping rule | Other (stated, no rule matched) |
| NCT02376933 | Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer | N/A | terminated | Mar 3, 2015 | University of Arizona | PI left the department; protocol transfer did not take place. | Investigator |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple…(PrE1003) | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | PrECOG, LLC. | Slow enrollment | Enrollment / accrual |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Aug 31, 2012 | NYU Langone Health | PI left the institution | Investigator |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel…(rev/abraxane) | Phase 1 / Phase 2 | terminated | Mar 3, 2014 | NYU Langone Health | PI left the institution | Investigator |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed… | Phase 1 / Phase 2 | terminated | Aug 27, 2012 | University Health Network, Toronto | The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015. | Drug supply |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed… | Phase 1 | terminated | Jun 4, 2015 | AbbVie | No Go decision for ABBV-838 | Other (stated, no rule matched) |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | Phase 1 | terminated | Jan 8, 2014 | Weill Medical College of Cornell University | The company providing one of the study drugs withdrew its support due to low enrollment. Therefore,… | Enrollment / accrual |
| NCT02986451 | Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | Phase 2 | withdrawn | Dec 8, 2016 | Sun Yat-sen University | not stated | Not stated |
| NCT03227432 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and… | Phase 2 | withdrawn | Jul 24, 2017 | Dana-Farber Cancer Institute | Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination… | Enrollment / accrual |
| NCT00124579 | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or… | Phase 2 | terminated | Jul 28, 2005 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT02720510 | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible,…(PANORAMA4) | Phase 2 | terminated | Mar 28, 2016 | Novartis Pharmaceuticals | A study was terminated due to low enrollment. | Enrollment / accrual |
| NCT01484626 | Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD) | Phase 1 / Phase 2 | terminated | Dec 2, 2011 | Loyola University | Celgene would no longer supply lenalidomide for the study | Drug supply |
| NCT02971410 | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory… | Early Phase 1 | withdrawn | Nov 23, 2016 | Wake Forest University Health Sciences | PI no longer interested in pursuing study. | Other (stated, no rule matched) |
| NCT00664378 | Efficacy Study of CYT997 in Multiple Myeloma | Phase 2 | terminated | Apr 22, 2008 | Gilead Sciences | Difficulty enrolling patients | Enrollment / accrual |
| NCT00538824 | Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed…(DexTR) | Phase 2 | terminated | Oct 3, 2007 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT01979276 | Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma) | Phase 1 / Phase 2 | terminated | Nov 8, 2013 | Weill Medical College of Cornell University | this study was terminated due to losing financial support, and enrollment challenges | Enrollment / accrual |
| NCT01174082 | Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma… | Phase 2 | terminated | Aug 3, 2010 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03023527 | Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | Phase 1 | terminated | Jan 18, 2017 | PETHEMA Foundation | Safety | Safety / toxicity |
| NCT02985333 | Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | Phase 2 | withdrawn | Dec 7, 2016 | Sun Yat-sen University | not stated | Not stated |
| NCT02372240 | A Study of VLX1570 and Dexamethasone in Myeloma Patients | Phase 1 / Phase 2 | terminated | Feb 26, 2015 | Vivolux AB | Dose limiting tox is observed. Study put on full clinical hold. | Other (stated, no rule matched) |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | Phase 1 / Phase 2 | terminated | Feb 29, 2008 | Milton S. Hershey Medical Center | Investigator decision | Investigator |
| NCT01382615 | Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research | — | terminated | Jun 27, 2011 | Dartmouth-Hitchcock Medical Center | Unable to fill cohort | Other (stated, no rule matched) |
| NCT02155634 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without… | Phase 3 | withdrawn | Jun 4, 2014 | Celgene | The study was terminated due to poor feasibility and lack of interest at the participating sites. | Other (stated, no rule matched) |
| NCT02732925 | To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in…(MELODY) | N/A | terminated | Apr 11, 2016 | Royal National Orthopaedic Hospital NHS Trust | Difficulties with recruitment due to change in referral rates. | Enrollment / accrual |
| NCT00909948 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following…(RLI) | Phase 1 | terminated | May 29, 2009 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT00113646 | Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for… | Phase 2 | terminated | Jun 10, 2005 | Massachusetts General Hospital | Expiration of MEDI-507 | Other (stated, no rule matched) |
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for… | Phase 2 | terminated | Jun 13, 2005 | Massachusetts General Hospital | Insufficient accrual | Enrollment / accrual |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple… | Phase 3 | terminated | Oct 27, 2009 | AEterna Zentaris | not stated | Not stated |
| NCT01315873 | Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | Phase 2 | terminated | Mar 15, 2011 | NYU Langone Health | PI left the institution before all data analysis was completed | Investigator |
| NCT01675141 | Lenalidomide Maintenance Therapy for Multiple Myeloma | Phase 2 | terminated | Aug 29, 2012 | National Cancer Institute (NCI) | Original investigator left the NIH and the primary outcome was not reached | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 30, 2019source: clinicaltrials